Tirbanibulin 1% Suppliers & Bulk Manufacturers

Available Forms: Ointment

Available Strengths: 1%

Reference Brands: Klisyri (USA)

Category: Derma Drugs

Tirbanibulin is a microtubule inhibitor that binds to tubulin and inhibits tubulin polymerization. It also inhibits Src‑kinase signalling pathways. By doing so, it arrests cell division in rapidly dividing skin cells affected by sun damage, leading to their death. It is used for the topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis on the face or scalp, helping clear precancerous skin lesions and reduce the risk of progression.

Product Description:

Tirbanibulin is a microtubule inhibitor. It binds tubulin, prevents microtubules assembling, and so arrests cells in mitosis — an effect that falls on rapidly dividing cells. It also inhibits Src kinase signalling. Actinic keratoses are proliferating dysplastic keratinocytes, and they take up the drug preferentially over surrounding normal skin.

It is used for actinic keratoses on the face and scalp, applied once daily for five consecutive days — the shortest course of any field treatment for this condition, against several weeks for imiquimod or fluorouracil. That brevity is the point: field treatments fail mainly because patients stop when the reaction becomes uncomfortable, and a five-day course is one most people complete. A local reaction with redness, flaking and crusting follows and peaks about a week after treatment, then settles over two to three weeks. Application to a defined area of around twenty-five square centimetres is specified, and contact with the eyes and mouth is avoided.

Sourcing notes. Originator product, on patent, no generic. Supplied in single-dose sachets covering one application, so the pack contains exactly one course — a packaging design that matters for dispensing and for cost comparison against multi-week alternatives. Registered in the US, EU and several other markets.